Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | HBB | P68871 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5989432 | 0.87 | FDPS (0.51) | FDPSHDAC1HDAC6LTA4HMKNK2 | |
| SCHEMBL27554271 | 0.79 | FDPS (0.47) | FDPSHDAC1HDAC6LTA4HMKNK2 | |
| SCHEMBL29139986 | 0.79 | FDPS (0.47) | FDPSHDAC1HDAC6LTA4HMKNK2 | |
| SCHEMBL595230 | 0.78 | FDPS (0.46) | FDPSHDAC1HDAC6LTA4HMKNK2 | |
| SCHEMBL2676961 | 0.77 | FDPS (0.44) | FDPSHDAC1HDAC6LTA4HMKNK2 | |
| SCHEMBL13281305 | 0.77 | FDPS (0.41) | FDPSHDAC1HDAC6LTA4HMKNK2 | |
| SCHEMBL1398869 | 0.75 | FDPS (0.41) | FDPSHDAC1HDAC6LTA4HMKNK2 | |
| SCHEMBL2894577 | 0.73 | FDPS (0.40) | FDPSHDAC1HDAC6LTA4HMKNK2 | |
| SCHEMBL28139965 | 0.73 | FGFR1 (0.43) | FDPSALDH1A1CYP3A4 | |
| SCHEMBL13857852 | 0.73 | FDPS (0.41) | FDPSHDAC1HDAC6ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 790 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220275366-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (SINA) | BANK OF AMERICA, N.A. | 2022-09-01 | — | — | US | disclosed |
| US-20220056441-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (SINA) | SIRNA THERAPEUTICS INC (US) | 2022-02-24 | — | — | US | disclosed |
| EP-3926046-A2 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA) | Sirna Therapeutics, Inc. (US) | 2021-12-22 | — | — | EP | disclosed |
| EP-3354656-B1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA) | SIRNA THERAPEUTICS INC (US) | 2021-04-07 | — | — | EP | disclosed |
| US-10889815-B2 | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2021-01-12 | — | — | US | disclosed |
| EP-3372684-B1 | SINGLE-STRANDED RNAI AGENTS CONTAINING AN INTERNAL, NON-NUCLEIC ACID SPACER | SIRNA THERAPEUTICS INC (US) | 2020-10-07 | — | — | EP | disclosed |
| US-10662428-B2 | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2020-05-26 | — | — | US | disclosed |
| US-10584335-B2 | Single-stranded RNAi agents containing an internal, non-nucleic acid spacer | SIRNA THERAPEUTICS, INC. (US) | 2020-03-10 | — | — | US | disclosed |
| US-20190233821-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) | BANK OF AMERICA, N.A. | 2019-08-01 | — | — | US | disclosed |
| US-10351852-B2 | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2019-07-16 | — | — | US | disclosed |
| WO-2003070895-A2 | RNA INTERFERENCE MEDIATED TREATMENT OF ALZHEIMER'S DISEASE USING SHORT INTERFERING NUCLEIC ACID (siNA) | RIBOZYME PHARMACEUTICALS, INC. (US) | 2003-08-28 | — | — | WO | disclosed |
| WO-2003070912-A2 | RNA INTERFERENCE MEDIATED INHIBITION OF EPIDERMAL GROWTH FACTOR RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2003-08-28 | — | — | WO | disclosed |
| WO-2003070884-A2 | RNA INTERFERENCE MEDIATED INHIBITION OF MDR P-GLYCOPROTEIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2003-08-28 | — | — | WO | disclosed |
| WO-2003070742-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF TELOMERASE GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) | RIBOZYME PHARMACEUTICALS, INC. (US) | 2003-08-28 | — | — | WO | disclosed |
| WO-2003070885-A2 | SHORT INTERFERING NUCLEIC ACID INHIBITION OF STEAROYL-CoA DESATURASE (SCD) GENE | SIRNA THERAPEUTICS, INC. (US) | 2003-08-28 | — | — | WO | disclosed |
| WO-2003070197-A2 | RNA INTERFERENCE MEDIATED INHIBITION OF TGF-BETA AND TGF-BETA RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2003-08-28 | — | — | WO | disclosed |
| WO-2003070910-A2 | INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VEGF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) | RIBOZYME PHARMACEUTICALS, INCORPORATED (US) | 2003-08-28 | — | — | WO | disclosed |
| WO-2003070750-A2 | RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS C VIRUS | SIRNA THERAPEUTICS, INC (US) | 2003-08-28 | — | — | WO | disclosed |
| US-20030148507-A1 | RNA interference mediated inhibition of prostaglandin D2 receptor (PTGDR) and prostaglandin D2 synthetase (PTGDS) gene expression using short interfering RNA | RIBOZYME PHARMACEUTICALS, INC. | 2003-08-07 | — | — | US | disclosed |
| US-20030143732-A1 | RNA interference mediated inhibition of adenosine A1 receptor (ADORA1) gene expression using short interfering RNA | RIBOZYME PHARMACEUTICALS, INC. | 2003-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10662428-B2 | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) | AGO2, SNRPE, SRRT | FDPS 2516/4885HDAC1 102/4885HDAC6 85/4885 |
| US-20220275366-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (SINA) | AGO2, SRRT, SNRPE | FDPS 1785/4885HDAC1 243/4885HDAC6 173/4885 |
| US-20030143732-A1 | RNA interference mediated inhibition of adenosine A1 receptor (ADORA1) gene expression using short interfering RNA | ADORA1, ADORA3, ADORA2A | FDPS 2859/4885HDAC1 3223/4885HDAC6 2889/4885 |
| US-20030148507-A1 | RNA interference mediated inhibition of prostaglandin D2 receptor (PTGDR) and prostaglandin D2 synthetase (PTGDS) gene expression using short interfering RNA | PTGDR, PTGDR2, HPGDS | FDPS 403/4885HDAC1 3821/4885HDAC6 3933/4885 |
| US-10889815-B2 | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) | AGO2, SNRPE, SRRT | FDPS 2516/4885HDAC1 102/4885HDAC6 85/4885 |
| US-20220056441-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (SINA) | AGO2, SNRPE, SRRT | FDPS 2516/4885HDAC1 102/4885HDAC6 85/4885 |
| US-20190233821-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) | AGO2, SNRPE, SRRT | FDPS 2516/4885HDAC1 102/4885HDAC6 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.